| NCT05781750 | A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE) | TERMINATED | PHASE2 | 2023-11-03 | 2024-11-08 | 2024-11-08 |
| NCT05569759 | A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) | COMPLETED | PHASE2 | 2023-05-23 | 2025-04-30 | 2025-04-30 |
| NCT05047536 | KZR-261 in Subjects With Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-09-30 | 2026-12 | 2025-12 |
| NCT04628936 | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. | COMPLETED | PHASE2 | 2020-11-04 | 2023-06-12 | 2023-03-10 |
| NCT04039477 | A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP | WITHDRAWN | PHASE2 | 2020-07 | 2020-08-05 | 2020-08-05 |
| NCT04033926 | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis | COMPLETED | PHASE2 | 2020-01-14 | 2022-04-06 | 2022-04-06 |
| NCT03393013 | A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis | COMPLETED | PHASE1, PHASE2 | 2018-02-20 | 2022-08-04 | 2022-08-04 |